• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Consumer Staples

Cramer: Barking Up the Right Tree With Pet Health Stocks

The Mars-VCA deal is yet another sign that pet health is a robust business.
By JIM CRAMER
Jan 09, 2017 | 01:59 PM EST
Stocks quotes in this article: WOOF, IDXX, ZTS, AMZN, BUFF, FRPT

We've been pounding the table on the humanization of pets as one of the great secular growth themes for so long that we had pretty much taken it for granted that everyone knew it.

What we didn't take for granted, however was that Mars, the privately held food giant that also happens to be one of the most sophisticated companies in the pet industry, would pay a gigantic premium for (WOOF) , today, WOOF being the symbol for VCA, better known as Veterinary Centers of America. Shareholders of VCA have to be thrilled with the 41% gain they walked into this morning, as Mars will put VCA alongside its own Banfield pet hospital chain, creating a dominant health-care company for companion animals.

Mars isn't new to the space. Besides health care, it offers two of the best premium food brands, Iams and Sheeba, both of which are respected as among the healthiest of offerings.

Why is this deal happening? A couple of reasons. First, the spending on companion animals has been compounding, and is among the highest rates of any consumer outlays as pets have moved from the basement to the bedroom and finally the bed. The numbers here are incredible: Americans' spending on pets has exploded in the 21st century, more than doubling since 2001 -- from $28.5 billion to $60.3 billion, according to the American Pets Products Association.

How can it not? Americans own 77.8 million dogs, representing 54.4 million households -- and 85.8 million cats, or 42.9 million households.

Second, pet care is often a cash business, no worries about reimbursement from the government. Third, there aren't that many large scale companies with big exposure to this group. I love equity scarcity, it bodes well for the other companies in the industry.

And who are the other companies? Let's start with Idexx Labs (IDXX) , the leader in pet health-care innovation which, like Mars, does diagnostics for vets. CEO Jonathan Ayers first put the humanization of pets thesis in front of us, and this company has stellar 10% organic growth, with huge gross margins. Idexx is a tech company, which constantly comes up with new products for vets. The latest, a urine sample diagnostics machine, has Ayers crowing about liquid gold.

We like Zoetis (ZTS) , the Pfizer spinoff that is largely focused on livestock animal health. It is a terrific business. And then there's Henry Schein HSIC, which is primarily a dental supply company that has moved aggressively into vet supplies.

We aren't as high on the pet food companies, in part because of pricing competition and in part because of Amazon (AMZN) , which has taken the margins out of a lot of these companies. We are lukewarm on both Blue Buffalo (BUFF) -- even as my dogs, Everest and Bug, go nuts for the stuff -- and Freshpet (FRPT) , which is the high-end refrigerated food business that we've found is too easily confused with the various human means we keep in the fridge.

That's another reason why the Mars bid for VCA makes so much sense. Anything that makes any company less dependent on pet food and more dependent on animal health is a winner.

I don't think the other companies are takeover targets. But I do think that Idexx can work its way higher over time. We'll miss VCA as part of the cohort, nevertheless it reminds us of how much more Idexx is worth than it currently sells for.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, has no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Consumer Staples | Healthcare | Markets | Mergers and Acquisitions | Stocks

More from Consumer Staples

Utz Brands Shares Could Be Worth a Nibble

Bruce Kamich
Mar 22, 2021 7:58 AM EDT

The charts of the snack maker are sending positive signals.

Jim Cramer: How Will Stocks That Thrived Amid Covid Do Post-Pandemic? Who Knows

Jim Cramer
Feb 5, 2021 6:54 AM EST

The forces that benefited shares of companies such as Peloton Interactive and Clorox may not sustain them once the impact of the virus subsides.

Altria Stock Is Ready to Light Up

Bruce Kamich
Jan 27, 2021 9:31 AM EST

Earnings for the tobacco company are set for Thursday.

My Top Stock Pick for 2021

Ed Ponsi
Dec 31, 2020 8:30 AM EST

Even after a solid 2020, this company has laid the groundwork for a successful 2021.

With Dividend Investing En Vogue, Here Are 4 More Stocks to Consider

Chris Versace
Dec 22, 2020 10:00 AM EST

The consistent annual dividend increases by this quartet even during bad times make them good income-investing bets going forward.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login